Quality of life in sexually active men with symptomatic benign prostatic hyperplasia: Effects of treatment

Clinical Drug Investigation

Volumn 25, Issue 4, 2005, Pages 219-230

  Daly, Mel P ^a,b  

^a GREATER BALTIMORE MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLANT EXTRACT; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SITOSTEROL; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; URTICA DIOICA EXTRACT;

ADULT; AGED; ALPHA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; DECISION MAKING; DISEASE SEVERITY; DIZZINESS; EJACULATION DISORDER; HUMAN; HYPOXIS; HYPOXIS ROOPERI; IMPOTENCE; LIBIDO DISORDER; MALE; MUSCLE WEAKNESS; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PYGEUM; QUALITY OF LIFE; REVIEW; RYE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SQUASH; SYMPTOMATOLOGY; URINARY TRACT; URTICA DIOICA;

EID: 17844392860     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525040-00001     Document Type: Review

References (58)

1. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline, Number 8. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994
2. Da Silva FC. Benign prostatic hyperplasia: natural evolution versus medical treatment. Eur Urol 1997; 32 Suppl. 2: 34-7
3. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 Guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 547-54
4. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58: 5-16
5. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000; 56 (5 Suppl. 1): 3-6
6. Arrighi HM, Metter EJ, Guess HA, et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy: the Baltimore Longitudinal Study of Aging. Urology 1991 ; 38: 4-8
7. Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998; 51: 578-84
8. Department of Veterans Affairs Cooperative Study of trans-urethral resection for benign prostatic hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993; 150: 1696-700
9. Lukacs B, Grange JC, Comet D, et al. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. Urology 2000; 55: 540-6
10. Garraway WM, Kirby RS. Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions. Urology 1994; 44: 629-36
11. Flomax® (tamsulosin hydrochloride) capsules: prescribing information. Physicians' Desk Reference®. 58th ed. Montvale (NJ): Thomson PDR, 2004: 1006-9
12. Barry MJ, Fowler Jr FJ, O'Leary MP, et al. Measurement Committee of the American Urological Association. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33 (4 Suppl.): AS145-55
13. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
14. Lukacs B, Comet D, Grange JC, et al. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. Br J Urol 1997; 80: 722-30
15. Helgason AR, Adolfsson J, Dickman P, et al. Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study. Age Ageing 1996; 25: 285-91
16. Kaiser FE. Sexuality in the elderly. Urol Clin North Am 1996; 23: 99-109
17. Panser LA, Rhodes T, Girman CJ, et al. Sexual function of men ages 40 to 79 years: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. J Am Geriatr Soc 1995; 43: 1107-11
18. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003; 44: 637-49
19. Baniel J, Israilov S, Shmueli J, et al. Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy. Eur Urol 2000; 38: 53-8
20. Barry MJ, Batista JE, Donovan J, et al. Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. 5th ed. London: UK Health Publication Ltd, 2001: 203-20
21. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol 2003; 5: 72-80
22. Hessels D, Verhaegh GW, Schalken JA, et al. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 2004; 4: 513-26
23. Barry MJ, Fowler Jr FJ, O'Leary MP, et al. for The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57
24. Calais Da Silva F, Marquis P, Deschaseaux P, et al. Relative importance of sexuality and quality of life in patients with prostatic symptoms: results of an international study. Eur Urol 1997; 31: 272-80
25. Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. 5th ed. London: Health Publication Ltd, 2001
26. Holtgrewe HL. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 1998; 51 Suppl. 4A: 1-7
27. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: current clinical experience. Urology 2001; 58 Suppl. 6A: 49-54
28. Roehrborn CG. Are all alpha-blockers created equal? An update. Urology 2002; 59 Suppl. 2A: 3-6
29. Kirby RS. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 33 Suppl. 2: 19-27
30. Downs TM, O'Leary MP. Sexual dysfunction in patients with benign prostatic hyperplasia. Curr Opin Urol 1999; 9: 9-14
31. 1-blocker. World J Urol 2002; 19: 405-12
32. de la Rosette JJ, Alivizatos G, Madersbacher S, et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 256-63
33. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13
34. van Kerrebroeck P, Jardin A, Laval KU, et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37: 306-13
35. Lukacs B, Grange JC, Comet D, et al. Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate Cancer Prostatic Dis 1998; 1: 276-83
36. Chappie CR. Medical therapy and quality of life. Eur Urol 1998; 34 Suppl. 2: 10-7
37. van Kerrebroeck P, Jardin A, van Cangh P, et al. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002; 41: 54-61
38. Debruyne FMJ. Alpha blockers: are all created equal? Urology 2000; 56 Suppl. 5A: 20-2
39. 1A-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-67
40. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology 1998; 51 Suppl. 4A: 46-9
41. Savage SJ, Spungen AM, Galea G, et al. Combination medical therapy for symptomatic benign prostatic hyperplasia. Can J Urol 1998; 5: 578-84
42. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
43. Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. for the PROS-CAR Long-Term Efficacy and Safety Study Group. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001; 57: 1073-7
44. Gormley GJ, Stoner E, Bruskewitz RC, et al. for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-91
45. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
46. O'Leary MP, Roehrborn C, Andriole G, et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003; 92: 262-6
47. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19: 413-25
48. Andriole GL, Kirby R. Safety and tolerability of the dual Salpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-8
49. Lowe FC. Phytotherapy in the management of benign prostatic hyperplasia. Urology 2001; 58 (6 Suppl. 1): 71-7
50. Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000; 163: 1451-6
51. Kadow C, Abrams PH. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia. Eur Urol 1986; 12: 187-9
52. Wilt TJ, Ishani A, Rutks I, et al. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 2000; 3: 459-72
53. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology 1998; 51 Suppl. 4A: 23-31
54. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9
55. Emberton M, Neal DE, Black N, et al. The effect of prostatectomy on symptom severity and quality of life. Br J Urol 1996; 77: 233-47
56. Kaplan SA. Minimally invasive alternative therapeutic options for lower urinary tract symptoms. Urology 1998; 51 Suppl. 4A: 32-7
57. Hammadeh MY, Madaan S, Singh M, et al. Two-year follow-up of a prospective randomised trial of electrovaporization versus resection of prostate. Eur Urol 1998; 34: 188-92
58. Riehmann M, Knes JM, Heisey D, et al. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995; 45: 768-75